ACADIA Pharmaceuticals Inc. (ACAD)

29.62
0.34 1.20
NASDAQ : Health Technology
Prev Close 29.28
Open 29.63
Day Low/High 29.14 / 30.03
52 Wk Low/High 13.17 / 30.38
Volume 147.03K
Avg Volume 1.24M
Exchange NASDAQ
Shares Outstanding 144.49M
Market Cap 4.28B
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)
Stocks Hold Onto Highs as Anxiety Over Looming Fed Rate Hike Eases

Stocks Hold Onto Highs as Anxiety Over Looming Fed Rate Hike Eases

Stocks look to erase the past two days of losses on Thursday, shooting higher on a rally among major U.S. banks.

Acadia Pharmaceuticals (ACAD) Stock Tanks Today on Delayed Regulatory Application

Acadia Pharmaceuticals (ACAD) Stock Tanks Today on Delayed Regulatory Application

Acadia Pharmaceuticals (ACAD) shares are down double digits after the company announced that it is delaying its application for regulatory approval of its Parkinson's disease treatment.

Stocks Rally as Banks Surge; Lumber Liquidators Shares Pop

Stocks Rally as Banks Surge; Lumber Liquidators Shares Pop

Stocks rally after two straight days of losses, led by the financial sector and a rebound in oil prices.

3 Stocks Reiterated As A Sell: FCX, ICPT, ACAD

3 Stocks Reiterated As A Sell: FCX, ICPT, ACAD

TheStreet Ratings team reiterated 3 stocks with a sell rating on Thursday

Stock Futures Post Modest Gains; Retail Sales Decline for Third Month

Stock Futures Post Modest Gains; Retail Sales Decline for Third Month

Stock futures post modest gains on Thursday morning in an attempted recovery after two days of losses which wiped out Wall Street's year-to-date gains.

Heavy Early Morning Activity On ACADIA Pharmaceuticals (ACAD)

Heavy Early Morning Activity On ACADIA Pharmaceuticals (ACAD)

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a pre-market mover with heavy volume candidate

ACADIA SHAREHOLDER ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation Of ACADIA Pharmaceuticals Inc.

ACADIA SHAREHOLDER ALERT: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation Of ACADIA Pharmaceuticals Inc.

Shareholder rights law firm Johnson & Weaver, LLP has commenced an investigation into whether certain officers and directors of ACADIA Pharmaceuticals Inc.

Acadia Drug Is Delayed Again as CEO Announces Retirement

Acadia Drug Is Delayed Again as CEO Announces Retirement

Acadia admits that it can't seek approval for its Parkinson's psychosis drug this quarter, as promised. The company's CEO also resigned.

ACADIA Pharmaceuticals Announces Retirement Of Uli Hacksell, Ph.D., Chief Executive Officer

ACADIA Pharmaceuticals Announces Retirement Of Uli Hacksell, Ph.D., Chief Executive Officer

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous...

ACADIA Pharmaceuticals Updates Planned Timing Of NUPLAZIDTM NDA Submission

ACADIA Pharmaceuticals Updates Planned Timing Of NUPLAZIDTM NDA Submission

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous...

Stock To Watch: ACADIA Pharmaceuticals (ACAD) In Perilous Reversal

Stock To Watch: ACADIA Pharmaceuticals (ACAD) In Perilous Reversal

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "perilous reversal" (up big yesterday but down big today) candidate

Market News: ACADIA, Escalera Resources, Urban Outfitters

Market News: ACADIA, Escalera Resources, Urban Outfitters

The stock markets in the United States declined today. Investors are becoming increasingly concern regarding the possibility that the Federal Reserve is close to making a decision to increase interest...

'Mad Money' Lightning Round: Allegiant Travel Good, Spirit Airlines Better

'Mad Money' Lightning Round: Allegiant Travel Good, Spirit Airlines Better

Cramer said Acadia Pharmaceuticals is good but speculative and he's ringing the register on Aruba Networks.

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan

What doesn't kill this market makes it stronger, Cramer says. His game plan includes Netflix, Berkshire Hathaway and Costco, among others.

ACADIA Pharmaceuticals Reports Financial Results For The Fourth Quarter And Year Ended December 31, 2014

ACADIA Pharmaceuticals Reports Financial Results For The Fourth Quarter And Year Ended December 31, 2014

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous...

ACADIA Pharmaceuticals To Present At Upcoming Investor Conferences

ACADIA Pharmaceuticals To Present At Upcoming Investor Conferences

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it...

ACADIA Pharmaceuticals To Announce Fourth Quarter And Full Year 2014 Financial Results On February 26, 2015

ACADIA Pharmaceuticals To Announce Fourth Quarter And Full Year 2014 Financial Results On February 26, 2015

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous...

Cushman & Wakefield: REITs Will Continue to Rock in 2015 – And Which Ones to Buy

Cushman & Wakefield: REITs Will Continue to Rock in 2015 – And Which Ones to Buy

In 2014, REITs outperformed the stock market. Cushman & Wakefield investment sales chairman analyzes the market and offers REITs to watch in 2015.

ACADIA Pharmaceuticals (ACAD) Highlighted As Weak On High Volume

ACADIA Pharmaceuticals (ACAD) Highlighted As Weak On High Volume

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a weak on high relative volume candidate

Biotech Investors Guide and Preview to the J.P. Morgan Healthcare Conference Part 1

Biotech Investors Guide and Preview to the J.P. Morgan Healthcare Conference Part 1

The much ballyhooed J.P. Morgan Healthcare Conference kicks off Monday in San Francisco. Here are capsule summaries of some of the expected story lines from presenting companies.

ACADIA Pharmaceuticals To Present At The 33rd Annual J.P. Morgan Healthcare Conference On January 13, 2015

ACADIA Pharmaceuticals To Present At The 33rd Annual J.P. Morgan Healthcare Conference On January 13, 2015

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it...

Today's Dead Cat Bounce Stock: ACADIA Pharmaceuticals (ACAD)

Today's Dead Cat Bounce Stock: ACADIA Pharmaceuticals (ACAD)

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "dead cat bounce" (down big yesterday but up big today) candidate

ACADIA Pharmaceuticals (ACAD) Is Water-Logged And Getting Wetter Today

ACADIA Pharmaceuticals (ACAD) Is Water-Logged And Getting Wetter Today

Trade-Ideas LLC identified ACADIA Pharmaceuticals (ACAD) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate

'Mad Money' Lightning Round: I Think You Should Buy, Buy, Buy Twitter

'Mad Money' Lightning Round: I Think You Should Buy, Buy, Buy Twitter

Cramer likes Acadia Pharmaceuticals and TrueCar but is avoiding Agrium.

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan

Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan

Cramer will be watching company earnings while keeping an eye on oil futures to get a sense of where the market will move.

ACADIA Pharmaceuticals Presents Caregiver Burden Data At The International Congress Of Non-Motor Dysfunctions In Parkinson's Disease And Related Disorders

ACADIA Pharmaceuticals Presents Caregiver Burden Data At The International Congress Of Non-Motor Dysfunctions In Parkinson's Disease And Related Disorders

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced the presentation of caregiver burden data from its Phase III program with NUPLAZID™ (pimavanserin) for Parkinson's disease psychosis (PDP) at the 10 th...

ACADIA Pharmaceuticals To Present At Upcoming Investor Conferences

ACADIA Pharmaceuticals To Present At Upcoming Investor Conferences

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced...

ACADIA Pharmaceuticals To Present At Jefferies 2014 Global Healthcare Conference On November 20, 2014

ACADIA Pharmaceuticals To Present At Jefferies 2014 Global Healthcare Conference On November 20, 2014

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central ...

ACADIA Pharmaceuticals Reports Third Quarter 2014 Financial Results And Updates Timing Of NUPLAZID™ NDA Submission

ACADIA Pharmaceuticals Reports Third Quarter 2014 Financial Results And Updates Timing Of NUPLAZID™ NDA Submission

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in neurological and related central ...

'Mad Money' Lightning Round: Buy, Buy, Buy Lockheed Martin

'Mad Money' Lightning Round: Buy, Buy, Buy Lockheed Martin

Cramer says Leucadia National is too dangerous for him, hold on to General Electric but wait on ConocoPhillips and Hess.

TheStreet Quant Rating: D (Sell)